FDA Moves Forward on Aducanumab
By
Phil Gutis
| August 7th, 2020
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
Mighty Mitochondria Could Prevent Alzheimer’s Neurodegeneration
By
Tanner Jensen
| July 27th, 2020
While most Alzheimer’s detection and prevention research is focused on the aggregation of tau tangles and amyloid beta proteins in the brain, some novel…
Phil’s Journal: Being Part of Scientific History, or, a New Phase of the Biogen Trial
By
Phil Gutis
| July 16th, 2020
The latest news about Biogen’s controversial Alzheimer’s drug popped into my email at 8:26 a.m. last Wednesday. Coincidentally it arrived just as I was…
Phil’s Journal: Waiting While Approval for Biogen’s Alzheimer’s Drug is Delayed, Yet Again
By Phil Gutis | April 23rd, 2020
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…
China’s ‘Seaweed’ Alzheimer’s Drug Is Now Available to Patients
By Lecia Bushak | December 30th, 2019
An experimental “seaweed” drug called Oligomannate, which treats Alzheimer’s, is now available for patients to buy in China. Chinese officials announced conditional approval to…
How Ultrasounds May Help Treat Alzheimer’s: Opening the Blood-Brain Barrier
By Phil Gutis | December 3rd, 2019
Reporting on a procedure performed last year, scientists at the West Virginia University Rockefeller Neuroscience Institute said today that using low-intensity focused ultrasound is…
Follow us